↓ Skip to main content

Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trial

Overview of attention for article published in The Lancet, September 2006
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (90th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (62nd percentile)

Mentioned by

patent
8 patents
f1000
1 research highlight platform

Citations

dimensions_citation
128 Dimensions

Readers on

mendeley
74 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trial
Published in
The Lancet, September 2006
DOI 10.1016/s0140-6736(06)69210-6
Pubmed ID
Authors

Daina Vanags, Bronwyn Williams, Barbara Johnson, Stephen Hall, Peter Nash, Andrew Taylor, Julissa Weiss, Dennis Feeney

Abstract

Chaperonin 10 (heat shock protein 10, XToll) has anti-inflammatory properties related to the inhibition of Toll-like receptor signalling pathways. Our aim was to establish whether chaperonin 10 is safe and effective in the treatment of rheumatoid arthritis.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 74 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 3 4%
Singapore 1 1%
Australia 1 1%
Unknown 69 93%

Demographic breakdown

Readers by professional status Count As %
Researcher 16 22%
Student > Bachelor 8 11%
Student > Ph. D. Student 7 9%
Student > Master 7 9%
Other 5 7%
Other 10 14%
Unknown 21 28%
Readers by discipline Count As %
Medicine and Dentistry 19 26%
Biochemistry, Genetics and Molecular Biology 7 9%
Agricultural and Biological Sciences 7 9%
Immunology and Microbiology 4 5%
Pharmacology, Toxicology and Pharmaceutical Science 3 4%
Other 10 14%
Unknown 24 32%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 October 2018.
All research outputs
#3,414,665
of 25,371,288 outputs
Outputs from The Lancet
#16,720
of 42,671 outputs
Outputs of similar age
#8,179
of 89,587 outputs
Outputs of similar age from The Lancet
#58
of 158 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 42,671 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 67.9. This one has gotten more attention than average, scoring higher than 60% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 89,587 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 158 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 62% of its contemporaries.